2.61
+0.13(+5.24%)
Currency In USD
| Previous Close | 2.48 |
| Open | 2.5 |
| Day High | 2.68 |
| Day Low | 2.47 |
| 52-Week High | 8.94 |
| 52-Week Low | 1.79 |
| Volume | 376,126 |
| Average Volume | 414,669 |
| Market Cap | 53.7M |
| PE | -1.99 |
| EPS | -1.31 |
| Moving Average 50 Days | 2.44 |
| Moving Average 200 Days | 3.17 |
| Change | 0.13 |
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Newsfile
Sep 02, 2025 11:30 AM GMT
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. M
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
Newsfile
Aug 21, 2025 11:30 AM GMT
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patientsPhiladelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ:
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
Newsfile
Aug 04, 2025 11:30 AM GMT
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus.Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medic